Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $10.60 Average Target Price from Analysts

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) have received an average rating of “Hold” from the ten research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $10.33.

A number of equities analysts recently commented on TEVA shares. Piper Sandler downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $11.00 to $7.00 in a research note on Wednesday, May 4th. Argus cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, January 27th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating and set a $11.00 price objective on the stock in a research report on Tuesday, April 12th. Sanford C. Bernstein upgraded shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $11.00 price objective on the stock in a research report on Friday, March 25th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 12th.

In other news, EVP Eli Shani sold 5,311 shares of the business’s stock in a transaction that occurred on Monday, February 28th. The shares were sold at an average price of $8.14, for a total value of $43,231.54. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP David Matthew Stark sold 6,452 shares of the business’s stock in a transaction on Monday, February 28th. The shares were sold at an average price of $8.14, for a total transaction of $52,519.28. The disclosure for this sale can be found here. Company insiders own 0.82% of the company’s stock.

Several institutional investors have recently bought and sold shares of TEVA. Fieldpoint Private Securities LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 100,000.0% in the 1st quarter. Fieldpoint Private Securities LLC now owns 3,003 shares of the company’s stock valued at $28,000 after acquiring an additional 3,000 shares during the last quarter. Koshinski Asset Management Inc. raised its position in shares of Teva Pharmaceutical Industries by 61.6% in the fourth quarter. Koshinski Asset Management Inc. now owns 3,934 shares of the company’s stock worth $32,000 after acquiring an additional 1,500 shares during the period. Kistler Tiffany Companies LLC increased its stake in shares of Teva Pharmaceutical Industries by 932.2% during the fourth quarter. Kistler Tiffany Companies LLC now owns 4,139 shares of the company’s stock worth $33,000 after purchasing an additional 3,738 shares in the last quarter. Huntington National Bank grew its stake in Teva Pharmaceutical Industries by 115.7% during the 4th quarter. Huntington National Bank now owns 4,850 shares of the company’s stock valued at $38,000 after acquiring an additional 2,601 shares in the last quarter. Finally, Aaron Wealth Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at about $603,000. Institutional investors own 45.79% of the company’s stock.

NYSE TEVA opened at $7.91 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.73 and a debt-to-equity ratio of 2.03. The business’s 50 day moving average is $8.74 and its two-hundred day moving average is $8.62. Teva Pharmaceutical Industries has a 12-month low of $7.23 and a 12-month high of $11.55.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last announced its earnings results on Tuesday, May 3rd. The company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. Teva Pharmaceutical Industries had a positive return on equity of 24.04% and a negative net margin of 3.95%. The firm had revenue of $3.66 billion for the quarter, compared to analysts’ expectations of $3.75 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 8.1% on a year-over-year basis. Research analysts anticipate that Teva Pharmaceutical Industries will post 2.4 earnings per share for the current year.

About Teva Pharmaceutical Industries (Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Read More

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.